Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 2/20 | 0.47 |
| ▸ | RHOA | P61586 | 2/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17362515 | 0.77 | SCN8A (0.52) | SCN8AKDM4EMITFGAAMEN1 | |
| SCHEMBL1969773 | 0.76 | IDO1 (0.39) | TACR1IDO1 | |
| SCHEMBL6948873 | 0.75 | RHOC (0.57) | RHOCRHOASCN8ATACR1IDO1 | |
| SCHEMBL31283347 | 0.74 | DUT (0.38) | DUT | |
| SCHEMBL3154124 | 0.73 | RHOC (0.49) | RHOCRHOASCN8ATACR1IDO1 | |
| SCHEMBL16257046 | 0.71 | DUT (0.33) | DUT | |
| SCHEMBL4256377 | 0.71 | RHOC (0.57) | RHOCRHOASCN8ATACR1IDO1 | |
| SCHEMBL16726935 | 0.71 | TACR1 (0.39) | TACR1IDO1KMT2A | |
| SCHEMBL6991073 | 0.71 | RHOC (0.56) | RHOCRHOASCN8ATACR1IDO1 | |
| SCHEMBL16727131 | 0.70 | IDO1 (0.41) | TACR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1513814-A4 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20050239829-A1 | Novel piperidine compound | TANABE SEIYAKU CO. LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1513814-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099787-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239829-A1 | Novel piperidine compound | EP300, BRD1, CBR3 | RHOC 2127/4885RHOA 4427/4885SCN8A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.